Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 6/20 | 0.47 |
| ▸ | SRC | P12931 | 2/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 8/20 | 0.45 |
| ▸ | AURKC | Q9UQB9 | 4/20 | 0.45 |
| ▸ | PLK4 | O00444 | 3/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.45 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.45 |
| ▸ | STK25 | O00506 | 1/20 | 0.45 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | GAK | O14976 | 1/20 | 0.45 |
| ▸ | MUSK | O15146 | 1/20 | 0.45 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.45 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.45 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.45 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3673996 | 0.81 | AURKA (0.46) | AURKBSRCGSK3BAURKAAURKC | |
| SCHEMBL3673997 | 0.81 | AURKA (0.46) | AURKBSRCGSK3BAURKAAURKC | |
| SCHEMBL648099 | 0.81 | AURKA (0.58) | AURKBSRCGSK3BAURKAAURKC | |
| SCHEMBL13765973 | 0.80 | AURKA (0.54) | AURKBSRCGSK3BAURKAAURKC | |
| SCHEMBL12341505 | 0.80 | AURKA (0.44) | AURKBSRCGSK3BAURKAAURKC | |
| SCHEMBL375565 | 0.78 | SMN1; SMN2 (0.48) | AURKBSRCGSK3BAURKAAURKC | |
| SCHEMBL62264 | 0.78 | AURKA (0.55) | AURKBSRCGSK3BAURKAAURKC | |
| SCHEMBL2203480 | 0.78 | AURKB (0.59) | AURKBSRCGSK3BAURKAAURKC | |
| SCHEMBL13785830 | 0.76 | AURKA (0.50) | AURKBSRCGSK3BAURKAAURKC | |
| SCHEMBL12338737 | 0.76 | AURKA (0.67) | AURKBSRCAURKAAURKCPLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1917259-B1 | PYRAZINE KINASE INHIBITORS | VERTEX PHARMA (US) | 2012-01-25 | — | — | EP | disclosed |
| US-7989456-B2 | Pyrazine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989456-B2 | Pyrazine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989456-B2 | Pyrazine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-02 | — | — | US | disclosed |
| US-20100222367-A1 | PYRAZINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100222367-A1 | PYRAZINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100222367-A1 | PYRAZINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-02 | — | — | US | disclosed |
| US-7737151-B2 | Pyrazine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-15 | — | — | US | disclosed |
| US-7737151-B2 | Pyrazine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-15 | — | — | US | disclosed |
| US-7737151-B2 | Pyrazine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-15 | — | — | US | disclosed |
| US-20070173516-A1 | Pyrazine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-07-26 | — | — | US | disclosed |
| US-20070173516-A1 | Pyrazine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-07-26 | — | — | US | disclosed |
| US-20070173516-A1 | Pyrazine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-07-26 | — | — | US | disclosed |
| WO-2007022384-A2 | PYRAZINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222367-A1 | PYRAZINE KINASE INHIBITORS | MAP3K5, MAP3K20, MAP3K1 | AURKB 402/4885SRC 229/4885GSK3B 466/4885 |
| US-20070173516-A1 | Pyrazine kinase inhibitors | MAP3K5, MAP3K20, MAP3K1 | AURKB 402/4885SRC 229/4885GSK3B 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.